Global Whole Exome Sequencing Market Size, Status and Forecast 2019-2025

Exome sequencing is a capture based method developed to identify variants in the coding region of genes which affect protein function. While exome capture methods using PCR, hybrid capture and molecular inversion probes exist, the most common and efficient strategies are in-solution capture methods. In-solution capture utilizes pools of oligonucleotides or probes bound to magnetic beads, whose sequence has been designed to hybridize to exon regions. After binding to genomic DNA, these probes are pulled down and washed, allowing exon regions to be selectively sequenced.
While there are approximately 180,000 exons in the human genome, constituting less than 2% of total sequence, the exome contains ~80-90% of known disease causing variants making it a cost-effective alternative to whole genome sequencing. When performing exome-seq, users should not only consider average on-target coverage but also the local coverage of particular sites of interest. When choosing between exome and whole genome sequencing (WGS), consider that exome sequencing has the advantage that oligonucleotides are designed to particular genomic regions where typical coverage with WGS is not enough for SNP calling. It is also more affordable enabling the analysis of more individuals and populations. With WGS, you can detect variants in regions not covered by exome capture allowing or the identification of structural and non-coding variants associated with disease.
The consumption of whole exome sequencing has exceeded 120 K samples per year. Whole exome sequencing is mainly produced by American companies. Mainly largest producers in the world are located in US.
The demand of whole exome sequencing service is very strong in Chinese market, especially in Beijing, Guangzhou and Shanghai. These cities have become the fastest-growing areas, because these cities continue to improve basic health care and scientific research.
In 2018, the global Whole Exome Sequencing market size was 180 million US$ and it is expected to reach 410 million US$ by the end of 2025, with a CAGR of 11.4% during 2019-2025.

This report focuses on the global Whole Exome Sequencing status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Whole Exome Sequencing development in United States, Europe and China.

The key players covered in this study
Illumina
Thermo Fisher
Roche
Angilent
Eurofins
Sengenics
Ambry
Macrogen
BGI
Novo Gene

Market analysis by product type
Agilent HaloPlex
Agilent SureSelect
Agilent SureSelect QXT
Illumina TruSeq Exome
Roche Nimblegen SeqCap
MYcroarray MYbaits

Market analysis by market
Correlation Research of Normal Human
Mendelian Disease and Rare Syndrome Gene Discovery
The Research of Complex Diseases
Mouse Exome Sequencing

Market analysis by Region
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Whole Exome Sequencing status, future forecast, growth opportunity, key market and key players.
To present the Whole Exome Sequencing development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Whole Exome Sequencing are as follows:
History Year: 2018-2019
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions